Latent – Weekly Recap

Latent is a clinical AI company focused on optimizing complex medication access and prior authorization workflows, and this weekly summary highlights a series of performance metrics from leading health systems. Recent discussions at Becker’s CPO Summit and new case studies underscore how Latent’s tools are being used to improve throughput, reduce backlogs, and expand capacity in pharmacy operations.

Health systems such as St. Luke’s and MetroHealth reported notable gains using Latent’s technology, with St. Luke’s cutting its prior authorization queue from about 2,400 to 600 in five months. MetroHealth reportedly shortened turnaround times from one to two months down to roughly two weeks, while Vanderbilt cleared 70 prior authorizations in under an hour, illustrating potential efficiency gains in administrative workflows.

Latent also showcased results from Ochsner Health’s Specialty Pharmacy, where AI-assisted drafting reduced average appeal letter creation time from about 30.6 minutes to 7.2 minutes. Benchmarking 91 appeals, Ochsner saw a 75–80% reduction in drafting time, reclaiming more than 35 work hours and enabling pharmacists to process more denials and devote additional time to direct patient care.

The company continued to highlight earlier outcomes at St. Luke’s Health System, where medication access referral backlogs reportedly dropped from roughly 2,300 items to under 800. St. Luke’s cut prior authorization turnaround times from seven days to three and reduced clinical review time from 18 minutes to five minutes per case, while handling about 1,200 additional authorizations per month with existing staff.

Latent’s updates emphasized that these improvements stem from both workflow redesign and its AI platform, including centralized disease-state pods and redeployment of staff into patient advocate roles. The company also stressed the importance of tight IT–operations alignment, citing collaborations with Tower Health and pharmacy leaders to ensure integration with existing systems, security requirements, and daily workflows.

For investors, the week’s developments reinforce Latent’s positioning as an enabler of scalable capacity expansion and measurable ROI in prior authorization and pharmacy workflows. Demonstrable reductions in backlogs and turnaround times, coupled with a focus on capacity creation rather than pure cost cutting, could strengthen Latent’s appeal to health systems and support recurring revenue growth in the healthcare AI segment.